Lifescien share price gained momentum following a string of USFDA approvals and a strategic investment announcement. On March 18, 2025, the company received final approval for Apalutamide Tablets, an androgen receptor inhibitor for metastatic castration-sensitive prostate cancer, to be produced at its Ahmedabad facility. This followed approvals on March 16 for Eluxadoline Tablets (75 mg and 100 mg) for irritable bowel syndrome with diarrhea (IBS-D) and on March 12 for Methenamine Hippurate Tablets (1 gram) for recurring urinary tract infections. The company also reported a successful USFDA inspection at its API Unit 1 in Ankleshwar, Gujarat, from March 10-14, concluding with no observations. Additionally, Zydus’ venture capital arm, Zynext Ventures USA LLC, invested in Illexcor Therapeutics, a biopharma firm focused on oral therapies for sickle cell disease. These developments highlight Zydus’ strong growth in oncology, gastroenterology, and innovative treatments, boosting investor confidence.

#StockInNews#Budget2025

1 like